Month: September 2026

Agreement provides dedicated commercial channel for REZENOPY^™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States

According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in annual sales across 9.8 million units

COMMACK, NY, Sept. 22, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that its wholly owned subsidiary, Scienture, LLC, has entered into an exclusive Sales, Marketing and Distribution Agreement with a distribution partner to provide opioid and substance-use disorder treatment centers nationwide with REZENOPY^™ (naloxone hydrochloride nasal spray 10 mg/0.11 mL) within the U.S. addiction treatment center market.

Under the agreement, REZENOPY^™ will be available exclusively through the distribution partner’s established customer network of approximately 2,000 OTP (Opioid Treatment Program) clinics and other Addiction Treatment Centers across the United States, expanding the product’s reach within the substance use disorder treatment market.

The agreement complements Scienture’s commercialization strategy and provides access to REZENOPY^™ within the defined addiction treatment center field. Scienture will continue to commercialize REZENOPY^™ outside this field through multiple concurrent commercial channels, including its existing and future wholesaler agreements, group purchasing organizations (“GPOs”), other distributors and customer relationships.

“This agreement represents an important expansion of our commercialization strategy for REZENOPY^™ and provides us with a dedicated channel into approximately 2,000 OTP Clinics and addiction treatment centers across the United States,” said Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings. “This strategic collaboration allows us to leverage established experience and relationships within the substance use disorder treatment market, making this relationship complementary to our broader commercialization efforts and provides an additional pathway to expand product availability while we continue building access through our wholesale, GPO, distributor and other institutional channels. As adoption expands across the OTP Clinic and Addiction Treatment Center networks, we believe this relationship has the potential to become a meaningful contributor to REZENOPY^™ revenue and support the continued growth of the franchise.”

“Expanding access to REZENOPY^™ among addiction treatment providers is an important component of our commercial strategy,” Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture. “We believe our distribution partner’s established presence in this market can help us efficiently reach treatment centers where naloxone availability is particularly relevant. As adoption develops, we believe this channel has the potential to contribute meaningfully to REZENOPY^™’s overall commercial growth alongside our other distribution initiatives.”

REZENOPY^™ is the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States, delivering 10 mg of naloxone hydrochloride in a single-use nasal spray device for the emergency treatment of known or suspected opioid overdose. Built on the proven naloxone molecule and a familiar nasal spray delivery platform, REZENOPY^™ is designed to provide an important treatment option for overdoses involving highly potent synthetic opioids. According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in annual sales across 9.8 million units, highlighting a substantial commercial opportunity for REZENOPY^™.

As previously disclosed, Scienture, LLC, a wholly-owned subsidiary of Scienture Holdings, Inc., entered into a definitive agreement with Summit Biosciences Inc. (a Kindeva subsidiary) in March 2025, for the exclusive U.S. commercialization rights to REZENOPY^™ (naloxone hydrochloride) Nasal Spray 10 mg, which received FDA approval on April 19, 2024.

About REZENOPY^™

REZENOPY^™ (naloxone hydrochloride) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.

REZENOPY^™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.

IMPORTANT SAFETY INFORMATION

• Administration: REZENOPY^™ nasal spray is for intranasal use only. Seek emergency medical care immediately after use. Administer a single spray into one nostril. If the patient does not respond within 2 to 3 minutes or responds and then relapses into respiratory depression, an additional dose may be given into the other nostril with a new device. Do not administer more than 2 sprays per day. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
• Contraindications: REZENOPY^™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
  Warnings and Precautions:
  • Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
  • Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
  • Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
  • Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
• Adverse Reactions: The following adverse reactions were observed in a REZENOPY^™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.
• Storage and Handling: Store REZENOPY^™ nasal spray in the blister and cartons provided. Store between 2°C to 25°C (36°F to 77°F). Excursions permitted up to 40°C (104°F). Do not freeze or expose to excessive heat above 40°C (104°F). Protect from light. REZENOPY^™ nasal spray may freeze at cold temperatures. If this happens, the device will not spray. If REZENOPY^™ nasal spray is frozen and is needed in an emergency, do NOT wait for it to thaw; get emergency medical help right away.

  For more detailed information, please refer to the full prescribing information provided by the FDA.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as REZENOPY™, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on The Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com

Pluxee releases a global study uncovering three paradoxes shaping employee engagement in the era of inflation and AI

Paris, September 22, 2026

Pluxee, a global player in employee benefits and engagement, today publishes its second international employee engagement study, surveying 11,000 respondents across 14 countries. The study highlights three paradoxes that offer a vivid snapshot of employee engagement today:

• While work plays a less central role in employees’ lives, their connection to their company grows stronger;

• Despite persistent financial pressure, employees are prepared to leave a job that no longer interests them;
• Although artificial intelligence is poised to profoundly transform employees’ jobs, it inspires more enthusiasm than fear.

 Aurélien Sonet, Chief Executive Officer of Pluxee, commented, “This second global study reveals a workforce that is far more optimistic than many might expect. In the context of economic uncertainty and pressure on purchasing power, employees are strongly connected to their companies, which they increasingly see as a source of stability in a challenging environment. The research also questions common perceptions about AI: while employees recognize its transformative potential for their jobs, most see it as an opportunity rather than a threat, expecting it to make work simpler and more interesting. As the world of work evolves rapidly and new skills become essential, the support we, as employers, provide our employees is crucial to driving their engagement.”

Key figures from the study   Inflation and purchasing power are employees’ number one concern, cited by 70% of employees globally (74% in France), including 25% who say they ‘can’t stop thinking about it’ (27% in France). Job satisfaction is higher than overall life satisfaction, with an average score of 7.6/10 vs. 7.3/10 globally (7.2/10 vs. 6.9/10 in France). Employees remain strongly connected to their organizations, with 87% saying they ‘love’ or ‘like’ their company, +4 points vs. 2025 (83% in France). More employees are adopting “Measured Engagement”, with 38% of employees globally engaging with work more intentionally to protect their boundaries, values and work-life balance, up 5 points since 2025. In France, this figure reaches 45%, up 9 points since 2025. Loyalty is becoming more conditional, with 33% of employees globally intending to stay with their company as long as their job remains interesting, +6 points since 2025. In France, this figure reaches 40%, +10 points vs. 2025. Well-being, recognition and benefits top employees’ HR priorities. Globally, well-being and working conditions rank first (35%), followed by recognition (33%) and employee benefits that complement compensation (29%). In France, the ranking follows a similar trend: well-being and working conditions (35%), recognition (34%) and employee benefits (21%). Employees are surprisingly optimistic about AI, with 65% expressing a positive attitude towards its use at work (51% in France), including 40% who say they “love” it (27% in France). Employees see AI as more of an opportunity than a threat: 40% are confident their job will not disappear as a result of AI (44% in France), while 42% believe AI will positively transform the content of their job (36% in France) Find the full research paper on the Pluxee website:  www.pluxeegroup.com/work-a-refuge-in-turbulent-times

An international study in 14 countries

Pluxee’s global employee engagement study explores how employees worldwide are experiencing work amid economic pressure and the rise of artificial intelligence. Conducted by Ipsos in May 2026 with 11,000 employees across 14 countries, the study tracks changes observed since the first edition in 2025. The countries surveyed include Belgium, Brazil, Chile, Colombia, France, Germany, Indiaⁱ, Italy, Mexico, Romania, Spain, Turkey, the UK and the USA.

The findings are analyzed by Jean-Baptiste Barféty, a public policy expert specializing in work, digital transition and the common good, and former advisor to the French Ministry of Labor, together with Antoine Solom, Senior Consultant at FOCUS, specializing in research, advisory and strategy for engaging transformations.

Three paradoxes shaping employee engagement

Despite mounting pressure on household budgets and the rapid transformation of work driven by AI, employees continue to demonstrate a surprising capacity to adapt and move forward with confidence. Contrary to many assumptions, the findings reveal a workforce that remains engaged, strongly connected to employers and broadly positive about work.

Yet beneath this resilience lie three striking paradoxes that capture the changing reality of employee engagement today.

While work is becoming less central to people’s lives, employees feel increasingly connected to their company

As reduced purchasing power and lower life satisfaction prompt employees to make bigger trade-offs at work to better focus on their personal lives, work is becoming less central to their lives. The share of employees who say work is the center of their lives has fallen from 19% to 13%, while “Measured Engagement”ⁱⁱ has increased from 34% to 38%, reflecting a growing tendency to engage with work more deliberately to protect boundaries, values and work-life balance.

This shift should not be mistaken for disengagement. On the contrary, employees’ connection to their organizations continues to grow: professional satisfaction remains high (above 7 in all countries), and 87% report they either ‘love’ or ‘like” their company, up four percentage points.

According to Jean-Baptiste Barféty, the workplace has become a reliable ‘refuge’ for employees, serving as a place of connection and “a shock absorber protecting them from some of the discomforts they might be experiencing because of inflation and global uncertainty”. 

Despite financial pressures, employees are prepared to leave jobs they no longer find interesting

Financial difficulties are having a tangible impact on workers’ lives, with 70% citing inflation and cost-of-living as their top worry and 25% saying they ‘cannot stop thinking about it’. In most of the countries studied, more than half of employees struggle to make ends meet, sometimes running out of money by the tenth day of the month.

However, despite a challenging context, employee loyalty is increasingly conditional: the percentage of employees who want to stay with their company ‘for as long as I can’ has fallen by 5 points compared to 2025. Meanwhile, the percentage of employees who ‘intend to stay as long as my job remains interesting’ is on the rise, increasing by 6 points globally.

Interesting work, the variety of tasks and recognition are driving employee engagement. This development reinforces a trend highlighted in the first edition of the study: employees expect reciprocity from their company in exchange for their engagement. Globally, when asked what their company’s HR priorities should be in the coming months, beyond higher salaries, employees’ top priorities are well-being and working conditions (35%), recognition of their commitment and achievements (33%), and employee benefits that complement compensation (29%).

Employees also expressed a need for growth, with 25% wishing to be ‘provided with better individual support and career development opportunities’ and 21% calling for their company’s HR to put developing ‘people’s skills through more training, particularly in AI’ at the top of their agenda.

AI is transforming jobs, yet employees see more opportunity than threat

While workers across the globe recognize that AI will be a major force in transforming the world of work, they are unexpectedly optimistic about its potential: 65% welcome the AI revolution, and 40% described AI as ‘great’ and say they ‘love’ using it.

This confidence is reflected in perceptions of AI’s impact on employment: 40% of employees are confident that their jobs will not disappear as a result of AI, and 42% concede that the content of their jobs will most likely change, ‘but in a positive way’, making work ‘less routine and more interesting’.

Employees are increasingly embracing AI and adapting to its growing role in the workplace. Among regular AI users, 39% say they learn to use the technology on their own, compared with just 9% who rely on managers and 9% on colleagues. With 31% of employees identifying improving efficiency as a key challenge for their organization in the years ahead, many employees view AI as a tool to save time, simplify work and reduce complexity.

The study also highlights a clear link between employee engagement and openness to AI. Using the Engagement Spectrum introduced in Pluxee’s 2025 global study The New Rules of Engagement, researchers found that the more engaged and outwardly curious employees are, the more likely they are to embrace AI. While 64% of “All Parts Engaged” employees say they love AI and use it frequently, this falls to 39% among “Work Centrists” and 27% among “Outsiders”.

Companies now face the challenge of ensuring that AI becomes the game-changer employees expect for efficiency and well-being, so that their current enthusiasm for the technology endures.

 ***

About Pluxee 

Pluxee is a global player in Employee Benefits and Engagement that operates in 28 countries. Pluxee helps companies attract, engage, and retain talent thanks to a broad range of solutions across Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits. Powered by leading technology and more than 5,600 engaged team members, Pluxee acts as a trusted partner within a highly interconnected B2B2C ecosystem made up of more than 500,000 clients, 37 million+ consumers and 1.7 million+ merchants. Conducting business for 50 years, Pluxee is committed to creating a positive impact on local communities, supporting well-being at work for employees and protecting the planet. 

For more information: www.pluxeegroup.com

Contact 
Cecilia de Pierrebourg  
+33 6 03 30 46 98  
cecilia.depierrebourg@pluxeegroup.com 

---

iTo ensure the comparability of results across markets, responses from India were excluded from the consolidated global analysis due to distinct response patterns observed within the dataset.

ii Pluxee’s global study published in 2025, The New Rules of Engagement was the first research paper to identify Measured Engagement, a trend in which employees engage with work deliberately to protect their boundaries, values, and work-life balance — a pragmatic response to a world of work that often expects people to overextend themselves.

Attachment

• Pluxee_PR_Work a refuge in turbulent times

Lille, Sept. 22, 2026 (GLOBE NEWSWIRE) — Top Wealth Group Holding Limited (NASDAQ: TWG)(“Top Wealth” or the “Company”), a distinguished purveyor of high-quality caviar and fine wines, today announced the relocation of its corporate headquarters from Hong Kong, China to Lille, France. This strategic move marks a pivotal step in the Company’s evolution from a regional Asian leader to a globally focused luxury food and beverage house.

The new Lille headquarters will serve as the command center for the Company’s international expansion, placing it at the heart of Europe’s luxury market and closer to key markets in the Americas, the Middle East, and the broader European continent. The relocation underscores the Company’s commitment to enhancing its global distribution capabilities and strengthening its presence in key international markets.

“Moving our head office to Lille is a natural progression for our Company as we pivot our operational focus from Asia to the world,” said Mr. Carp Lee, CEO of the Company. “France is the global capital of luxury, gastronomy, and fine wine, making it the ideal base for our next chapter. This move positions us to better serve our growing international clientele, forge deeper relationships with premier distributors, and elevate our brands to a new echelon of global prestige.”

The decision comes as the Company accelerates its global expansion, following a recent series of distributorship agreements covering key markets, including locations in Europe, the Middle-east, and Asia . The Company’s management forecasts that total revenue for the current financial year will increase by more than 30% compared to the previous year, driven by strong demand in these new markets.

“Our vision has always been to bring the world’s finest caviar and wine to discerning customers everywhere,” added Carp Lee. “This headquarters relocation is not just a change of address; it is a declaration of our global ambitions. We are excited to build on our Hong Kong heritage while embracing the opportunities that France and the global market offer.”

The Company will maintain a significant operational presence in Hong Kong, continuing to serve its valued Asian clientele as it expands its footprint worldwide.

About Top Wealth Group Holding Limited

The Company is a leading supplier of premium-class sturgeon caviar and light luxury wines. The Company sources and distributes products with the highest standards of quality and authenticity, holding permits and certifications that underscore its commitment to sustainability and excellence. The Company supplies caviar under private labels and through its own luxury brand, renowned for its exceptional quality and taste. With a heritage rooted in Asia and a new home in France, the Company is dedicated to providing unforgettable epicurean experiences to the global market.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in verbal statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of the press release, and the Company undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

Top Wealth Group Holding Limited
Investor Relations
Email: ir@topwealth.cc

Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date

No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001’s differentiated safety profile as an IL-12-based immunotherapy

MRD study has now demonstrated the safety and tolerability of IMNN-001 both in combination with bevacizumab and in the maintenance setting

Recommendation follows encouraging preliminary Phase 2 MRD data reported in July demonstrating evidence of deeper anti-tumor activity and immune activation

LAWRENCEVILLE, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Independent Data Monitoring Committee (IDMC) overseeing its ongoing Phase 2 minimal residual disease (MRD) translational study of IMNN-001 has reviewed all safety data to date and recommended that the study continue without modification after identifying no new safety signals and confirming comparable safety across both treatment arms.

The IDMC is comprised of independent medical experts in gynecologic cancers. The Phase 2 MRD study is a randomized, controlled translational study assessing minimal residual disease following treatment with standard-of-care chemotherapy and bevacizumab, with or without IMNN-001, in women with newly diagnosed advanced ovarian cancer. The multi-site study is being conducted in collaboration with Break Through Cancer and is led by investigators at The University of Texas MD Anderson Cancer Center.

“The IDMC’s recommendation to continue our Phase 2 MRD study without modification provides important independent validation of the favorable safety profile we have consistently observed across our clinical development program,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “Across our completed and ongoing clinical studies, we have observed no cytokine release syndrome, no systemic toxicities and no serious immune-related adverse events—an important distinction for an IL-12-based immunotherapy. Combined with the encouraging biological and clinical activity reported from this study in July, these findings further strengthen our confidence as we continue advancing our pivotal Phase 3 OVATION 3 trial.”

Consistent with this experience, the latest IDMC review identified no new safety concerns in the ongoing pivotal Phase 3 OVATION 3 trial. The MRD study has also achieved two important safety objectives by demonstrating the safety and tolerability of IMNN-001 both in combination with bevacizumab and in the maintenance setting.

In July 2026, the Company reported encouraging preliminary data from the MRD study, which is designed both to evaluate clinical activity and to better understand how IMNN-001 remodels the tumor immune microenvironment following frontline treatment. Among patients who reached the study’s primary assessment at second-look laparoscopy, treatment with IMNN-001 was associated with:

• A lower rate of MRD positivity compared with the control arm (44% versus 67%);
• Higher clearance of circulating tumor DNA (ctDNA) (87.5% versus 62.5%); and
• A higher proportion of patients achieving “no evidence of disease” following frontline therapy (100% versus 56%).

While preliminary and based on a limited number of patients, these findings provide encouraging evidence that IMNN-001 may drive deeper anti-tumor responses while maintaining the highly favorable safety profile consistently observed across the Company’s clinical development program. These clinical findings are supported by translational analyses that demonstrated robust IL-12 expression within macrophages, activation of downstream cytokines including interferon-gamma, and evidence of both macrophage and T-cell activation, consistent with remodeling the tumor immune microenvironment from an immunologically “cold” state to one that is immunologically active, or “hot.”

About the Translational Phase 2 MRD Study

The Phase 2 MRD study (NCT05739981) is evaluating IMNN-001 in combination with standard-of-care neoadjuvant and adjuvant chemotherapy plus bevacizumab in women with newly diagnosed advanced ovarian cancer, conducted through the Break Through Cancer Targeting Minimal Residual Disease in Ovarian Cancer TeamLab. Patients in the experimental arm receive IMNN-001, administered intraperitoneally, in combination with N/ACT plus bevacizumab, followed by interval cytoreductive surgery and additional cycles of adjuvant chemotherapy plus IMNN-001. Patients then undergo second-look laparoscopy (SLL) to assess for minimal residual disease, followed by maintenance therapy assigned according to homologous recombination deficiency (HRD) status. The primary endpoint of the study is MRD-positive rate at SLL; the secondary endpoint is progression-free survival (PFS). The study also includes serial translational analyses of tumor tissue, circulating tumor DNA (ctDNA), microbiome, and intraperitoneal fluid, to further characterize IMNN-001’s impact on the tumor immune microenvironment.

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas^® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity, acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer, and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.

About Epithelial Ovarian Cancer

Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately 70% are diagnosed in advanced stage III/IV. Epithelial ovarian cancer is characterized by dissemination of tumors in the peritoneal cavity with a high risk of recurrence (75%, stage III/IV) after surgery and chemotherapy. Since the five-year survival rates of patients with stage III/IV disease at diagnosis are poor (41% and 20%, respectively), there remains a need for a therapy that not only reduces the recurrence rate but also improves overall survival. The peritoneal cavity of advanced ovarian cancer patients contains the primary tumor environment and is an attractive target for a regional approach to immune modulation.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA-based gene therapy technology across its modalities. The first modality, TheraPlas^®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy being developed for the localized treatment of advanced ovarian cancer. IMNN-001 has been evaluated in multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently being studied in the ongoing Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

About Break Through Cancer

Founded in 2021, Break Through Cancer empowers outstanding researchers and physicians to both intercept and find cures for several of the deadliest cancers by stimulating radical collaboration among outstanding cancer research institutions, including its founding partners: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and The University of Texas MD Anderson Cancer Center.

The Foundation is supported by a Board of Directors from the five partner institutions and a Scientific Advisory Board of U.S. cancer experts. The Foundation was launched with an extraordinary challenge pledge of $250 million from Mr. and Mrs. William H. Goodwin, Jr. and their family, and the estate of William Hunter Goodwin III.

For further information, please visit the Foundation’s website at www.breakthroughcancer.org.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	NextEnergy Solar Fund Ltd
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	21/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	Ordinary NPV
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	5,812,009	1.01%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	5,812,009	1.01%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
Ordinary NPV	Sale	10,000	49.23p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
Ordinary NPV

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	22/09/2026
Contact name:	Lydia Cotterill – Compliance Department
Telephone number:	0151 237 1176

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.